Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-24T05:59:06.591Z Has data issue: false hasContentIssue false
  • English
  • Français

Recent antipsychotics in the treatment of psychoses

Published online by Cambridge University Press:  18 September 2015

M.J.A.J.M. Hoes
Get access Rights & Permissions [Opens in a new window]

Summary

Antipsychotic drugs are effective in psychoses, whatever the etiology of the disorder. The positive symptoms tend to respond more readily. The need for developing new drugs arises from the refractoriness of the negative symptoms, the 10-25% of the patients that are treatment-resistant and the problems of short-, and long-term extrapyramidal side-effects. Thus far, six drugs, differing from the classical antipsychotics, have been licensedfor use: olanzepine, risperidone and quetiapine; the longest registration exists for sulpiride and clozapine while the most recent one is for amisulpride. This review starts with a brief introduction to symptomatology, and takes differences with the classical drugs in pharmacology, pharmacokinetics, clinical aspects and side-effects into consideration. Clozapine, risperidone and sulpiride may be considered for clinical use in refractory patients; these three, olanzapine and amisulpride when extrapyramidal side-effects cause a clinical problem. Amisulpride and sulpiride have a dual therapeutic acion: On negative symptoms at low dose, on positive symptomen at high doses.

Keywords

Antipsychoticatypical antipsychoticpsychosismanagementamisulprideclozapineolanzapinequetiapinerisperidonesulpirideAntipsychoticumatypisch antipsychoticumpsychose behandelingamisulprideclozapineolanzapinequetiapinerisperidonesulpiride
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 11 , Issue 3 , September 1999 , pp. 85 - 92
Copyright
Copyright © Cambridge University Press 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literature

1.Nijdam, SJ. Ervaringen met moderne psychofarmaca. Den Haag: Mouton, 1966.Google Scholar
2.Shepherd, M. Neurolepsis and the psychopharmacological revolution: myth and reality. Hist Psychiat 1994; 5: 89–97.CrossRefGoogle Scholar
3.Hoes, MJAJM. Psychofarmacotherapie: geschiedenis. Acta neuropsychiat 1994; 6: 48–56.CrossRefGoogle Scholar
4.Kerwin, RW. The new atypical antipsychotics. Br J Psychiat 1994; 164: 141–9.CrossRefGoogle ScholarPubMed
5.Hoes, MJAJM. Klinische keuzecriteria voor antipsychotica. In: Hoes, MJAJM, Nijdam, SJ, Hekster, YA, red. Praktische keuzecriteria voor Psychofarmaca. Een eerstelijnshandleiding. Alphen a/d Rijn: van Zuiden Communications, 1995: 13–20.Google Scholar
6.Hoes, MJAJM. Atypische antipsychotica. GeBu 1995; 29: 23–7.Google Scholar
7.Beasly, CM, Sanger, T, Satterlee, W, et al.Olanzapine versus placebo: result of a double-blind, six-dose olanzapinetrial. Psychopharmacol 1996; 124: 159–67.CrossRefGoogle Scholar
8.Beasly, CM, Tollefson, G, Tran, P, et al.Olanzapine versus placebo and haloperidol. Acute phase results of the North American double blind olanzapine trial. Neuropsychopharmacol 1996; 14: 111–23.Google Scholar
9.Bymaster, FP, Calligaro, DO, Falcone, JF, et al.Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacol 1996; 14: 87–96.CrossRefGoogle ScholarPubMed
10.Casey, DE. ‘Seroquel’ (quetiapine): preclinical and clinical findings of a new atypical antipsychotic. Exp Opin Invest Drugs 1996; 5: 939–57.CrossRefGoogle Scholar
11.Fulton, B, Goa, KL. ICI-204, 636. An initial appraisal of its pharmacological properties and clinical potential in the treatment of schizophrenia. CNS Drugs 1995; 4: 68–78.CrossRefGoogle Scholar
12.Goldstein, JM. Pre-clinical pharmacology of new atypical antipsychotics in late stage development. Exp Opin Invest Drugs 1995; 4: 291–8.CrossRefGoogle Scholar
13.Coukell, AJ, Spencer, CM, Benfield P., Amisulpride. Areview of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 1996;6:237–56.CrossRefGoogle Scholar
14.Arndt, J, Skarsfeldt, T. Do novel antipsychotics have similar phrmacological characteristics? A review of the evidence. Neuropsychopharmacol 1998; 18: 63–101.CrossRefGoogle Scholar
15.Leysen, JE, Janssen, PMF, Schotte, A, Luyten, WHML, Megens, AHP. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacol 1993; 112: S40–54.CrossRefGoogle Scholar
16.DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th Ed. Washington DC: APA, 1994.Google Scholar
17.Dilling, H, Mombour, W, Schmidt, MH. Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F). Bern: Huber, 1991.Google Scholar
18.Berrios, G. Delirium and cognate states. In: Berrios, G, Porter, R, eds. A History of Clinical Psychiatry. London: Athlone Press, 1995:13–23.Google Scholar
19.Kuipers, Th. Stille waters….Over de meting en beoordeling van negatieve Symptomen. Utrecht: Academisch Proefschrift, 1992.Google Scholar
20.Andreasen, NC. Negative symptoms in schizophrenia: definition and reliability. Arch gen Psychiat 1982; 39: 784–9.CrossRefGoogle ScholarPubMed
21.Kay, SR. Positive and negative syndromes in schizophrenia. In: Praag, HM van, ed. Clinical and Experimental Psychiatry Monograph 5. New York: Brunner/Mazel, 1991.Google Scholar
22.Baldessarini, RJ, Frankenburg, FR. Clozapine. A novel antipsychotic agent. New Engl J Med 1991; 324: 746–54.Google ScholarPubMed
23.Angst, J, Bech, P, Bobon, Det al.Report on the third consensus conference on the methodology of clinical trials with antipsychotic drugs. Pharmacopsychiat 1991; 24: 149–52.CrossRefGoogle ScholarPubMed
24.Anonymous, . Long-term management of people with psychotic disorders in the community. Drug Ther Bull 1994; 32: 73–7.Google Scholar
25.Richelson, E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J clin Psychiat 1996; 57 (suppl 11): 4–11.Google ScholarPubMed
26.Scatton, B, Claustre, Y, Cudennec, A, Oblin, A, Perrault, G, Sanger, DJ, Schoemaker, H. Amisulpride: from animal pharmacology to therapeutic action. Int clin Psychopharmacol 1997; 12 (suppl 2): 29–37.CrossRefGoogle ScholarPubMed
27.Schoemaker, H, Claustre, Y, Fage, D, et al.Neurochemical characteristics of amisulpride, an atypical dopamine D2 /D3 receptor antagonist with both presynpatic and limbic selectivity. J Phamacol exp Ther 1997; 280: 83–97.Google Scholar
28.Louwerens, JW, Buddingh, JA, Zijlstra, S, et al.Dopamine (D2) receptor occupancy in clozapine-treated patients as measured by positron emission tomography using 18FESP. In: Brunallo, M, Mendlewicz, J, Racagni, G, red. New Generation of antipsychotic Drugs: Novel Mechanism of Action. Biomed Drug Res 1993; 4: 130–5.Google Scholar
29.Jenner, P. The mode of action of neuroleptic drugs. In: Gorrod, JW, Gibson, GG, Mitchard, et al., red. Development of Drugs and modern Medicine: a conference in honour of Prof. Beckett, AH. Chichester: VHC, 1986: 117–32.Google Scholar
30.Wagstaff, AJ, Fitton, A, Benfield, P. Sulpiride, A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in schizophrenia. CNS Drugs 1994; 2; 313–33.Google Scholar
31.Perrault, GH, Depoortere, R, Morel, E, Sanger, DJ, Scatton, C. Psychopharmacological profile of amisulpride: An antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. Pharmacol exp Ther 1997; 280: 73–82.Google ScholarPubMed
32.Marder, SR, Melbach, RC. Risperidone in the treatment of schizophrenia. Am J Psychiat 1994; 151: 825–35.Google ScholarPubMed
33.Boer, JA den. Risperidon. Acta neuropsychiat 1995; 7: 84–94.Google Scholar
34.Peuskens, J. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multicentre, double-blind, parallel-group study versus haloperidol. Br J Psychiat 1995; 166:712–26.CrossRefGoogle ScholarPubMed
35.Weiden, PJ. Quetiapine (‘Seroquel’): A new ‘Atypical’ antipsychotic. J Prac Psych Behav Health 1997; 3: 368–74.Google Scholar
36.Meats, P. Quetiapine (‘Seroquel’); an effective and well-tolerated atypical antipsychotic. Int J Psychiat clin Prac 1997; 1: 231–9.CrossRefGoogle ScholarPubMed
37.Freeman, HL. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies. Int clin Psychopharmacol 1997; 12 (sullp 2): 11–19.CrossRefGoogle ScholarPubMed
38.Puech, A, Fleurot, O, Rein, W, Amisulpride Study Group. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. Haloperidol. Acta psychiat scand 1998; 98: 65–72.CrossRefGoogle Scholar
39.Möller, HJ, Boyer, P, Fleurot, O, Rein, W. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacology 1997; 132: 396–401.Google ScholarPubMed
40.Fleurot, O, Bech, P, Turjanski, S. Amisulpride versus risperidone in the treatment of acute schizophrenia. Biol Psychiat 1997; 42: 65–170.CrossRefGoogle Scholar
41.Wetzel, H, Gründer, G, Hillert, A, Philip, M, Gattaz, WF, Sauer, H, Adler, G, Schröder, J, Rein, W, Benkert, O, Amisulpride Study Group. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology – a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1 /D2-like antagonist. Psychopharmacology 1998; 137: 233–32.CrossRefGoogle Scholar
42.Chabannes, JP, Pelissolo, A, Farah, S, Gerard, D. Evaluation de l'efficacité et de la tolérance de l'amipsulpride dans le traitement des psychoses schizophréniques. L'Encéphale 1998; 24: 386–92.Google Scholar
43.Colonna, L, Saleem, P, Dondey-Nouvel, L, Rein, W, Amisulpride Study group. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int Clin Psychopharmacol 1999; in press.Google Scholar
44.Justin-Besançon, L. Die Benzamide – Entdeckung und Entwicklung in der Psychiatrie. In: Linde, OK, ed. Pharmakopsychiatrie im Wandel der Zeit. Klingenmünster: Tilia, 1988: 349–71.Google Scholar
45.Loo, H, Poirirer-Littre, M-F, Theron, M, Rein, W, Fleurot, O. Amisulpride versus placebo in the medium-term treatment of negative symptoms of schizophrenia. Br J Psychiat 1997; 170: 18–22.CrossRefGoogle ScholarPubMed
46.Danion, J-M, Rein, W, Fleurot, O, Amisulpride Study Group. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Am J Psychiat 1999; 156: 610–6.CrossRefGoogle Scholar
47.Paillère-Martinot, M-L, Lecubrier, Y, Martinot, J-L, Aubin, F. Improvement of some schizophrenic symptoms with low doses of amisulpride. Am J Psychiat 1995; 152: 130–3.Google ScholarPubMed
48.Boyer, P, Lecubrier, Y, Puech, AJ, Dewailly, J, Aubin, F. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiat 1995; 166: 68–72.CrossRefGoogle ScholarPubMed
49.Rein, W, Turjanski, S. Clinical update on amisulpride in deficit schizophrenia. Int clin Psychopharmacol 1997; 12 (sullp 2): 19–29.CrossRefGoogle ScholarPubMed
50.JC, , Barnes, TRE, Curson, DA, Pantelis, C, Alberts, JL. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. Haloperidol. Br J Psychiat 1997; 171: 564–8.Google Scholar
51.Marder, SR, Putten, Th van. Who should receive clozapine? Arch gen Psychiat 1988; 45: 865–7.CrossRefGoogle ScholarPubMed
52.Carman, J, Peuskens, J, Vangeneugden, A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int clin Psychopharmacol 1995; 10: 207–13.CrossRefGoogle ScholarPubMed
53.Schooler, NR. Negative symptoms in schizophrenia: assessment of the effect of risperidone. J clin Psychiat 1994; 55 (5, suppl): 22–8.Google ScholarPubMed
54.Selten, J-PJC. Neurolepsie en akinesie. Tijdschr Psychiat 1991; 33: 62–5.Google Scholar
55.Kane, JM, Honigfeld, G, Singer, J, Meitzer, HY. Clozaril study group. Clozapine for the treatment resistant schizophrenic. Arch gen Psychiat 1988; 45: 789–96.CrossRefGoogle Scholar
56.Piekar, D, Owen, R, Litman, RE, Konicki, E, Guttierez, R, Rapaport, MH. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch gen Psychiat 1992; 49: 345–53CrossRefGoogle Scholar
57.Kane, JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiat 1992; 160 (suppl 17): 41–6.CrossRefGoogle Scholar
58.Honigfeld, G, Patin, J. A two-year clinical and economic follow-up of patients on clozapine. Hosp Comm Psychiat 1990; 41: 882–5.Google ScholarPubMed
59.Revicki, DA, Luce, BR, Weschler, JMet al.Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Comm Psychiat 1990; 41: 850–4.Google ScholarPubMed
60.Claus, A, Bollen, J, De Cuyper, H, et al.Risperidone versus haloperidol in the treatment of chronic schizophrenic in-patients: a multi-centre, double-blind comparative study. Acta psychiat scand 1992; 85: 295–305.CrossRefGoogle Scholar
61.Addington, DE, Jones, B, Bloom, D, Chouinard, G, Remington, G, Albright, P. Reduction of hospital days in chonic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993;15:917–26.Google Scholar
62.Lindström, LH. The effect of long-term treatment clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta psychiat scand 1988; 77: 524–9.CrossRefGoogle ScholarPubMed
63.Lindström, E, Eriksson, C, Hellgren A et al.Efficacy of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995; 17: 402–12.CrossRefGoogle ScholarPubMed
64.Möller, HJ. Open study on the long-term treatment of chronic schizophrenic patients with risperidone, analysis of efficacy and safety data. Beerse: Janssen Research Foundation, 1993 data on file.Google Scholar
65.Alphen, EEM van, Kuipers, T. Farmacotherapie bij een postpsychotische depressie. GeBu 1996; 30: 137–41.Google Scholar
66.Rein, W, Fleurot, O, Turianski, S. Amisulpride improves affective symptoms in acute schizophrenia. Eur Neuropsychopharmacol 1998; 8: abstract P.2.061, S231.CrossRefGoogle Scholar
67.Jann, MW, Grimsley, SR, Gray, EC, Chang, W-H. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokin 1993; 24: 161–75.CrossRefGoogle ScholarPubMed
68.Ereshefsky, L. Pharmacokinetics and drug interactions: update for new antipsychotics. J clin Psychiat 1996; 57 (suppl 11): 12–25.Google ScholarPubMed
69.Levy, G. A pharmacokinetic perspective on medication non-compliance. Clin Pharmacol Ther 1993; 54: 242–5.CrossRefGoogle Scholar
70.Kane, JM, Woerner, M, Lieberman, J. Tardive dyskinesia: prevalence, incidence and risk factors. J clin Psychopharmacol 1988; 8:52–65.CrossRefGoogle ScholarPubMed
71.Anderson, ES, Powers, PS. Neuroleptic malignant syndrome associated with clozapine use. J clin Psychiat 1991; 52: 102–5.Google ScholarPubMed
72.Prikbord, . Agranulocytosis. GeBu 1991; 25: 10.Google Scholar
73.Prikbord, . Risperidon. Gebu 1994; 28: 94.Google Scholar
74.Sachdev, P, Kruk, J, Kneebone, M, Kissane, D. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J clin Psychopharmacol 1995; 15: 365–71.CrossRefGoogle ScholarPubMed
75.Webster, P, Wijeratne, Ch. Risperidone-induced neuroleptic malignant syndrome. Lancet 1994; 344: 1228–9.CrossRefGoogle ScholarPubMed
76.Chouinard, G, Jones, B, Remington, Get al.A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J clin Psychopharmacol 1993; 13: 25–40.CrossRefGoogle ScholarPubMed
77.Grant, S, Filton, A. Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994; 48: 253–73.CrossRefGoogle ScholarPubMed
78.Ford, B, Lynch, T, Greene, P. Risperidone for Parkinson's disease. Lancet 1994; 344: 681.CrossRefGoogle ScholarPubMed
79.Meco, G, Alessandria, A, Bonifati, V, Giustini, P. Risperidone for hallucinations in levo-dopa-treated Parkinson's disease. Lancet 1994;344:681.Google Scholar
80.Singh, AN, Catalan, J. Risperidone in HIV-related manic psychosis. Lancet 1994; 344: 1029–30.CrossRefGoogle ScholarPubMed
81.Touw, DJ, Verhoeven, WMA, Noten, JBGM. Het cytochroom P450 enzymsysteem. Wat is de relevantie voor de praktijk? Deel I: De isoenzymen. Acta neuropsychiat 1998; 10: 34–43.CrossRefGoogle Scholar
82.Touw, DJ, Verhoeven, WMA, Noten, JBGM. Het cytochroom P450 enzymsysteem. Wat is de relevantie voor de praktijk? Deel II: Interacties. Acta neuropsychiat 1998; 10: 58–63.CrossRefGoogle ScholarPubMed
83.Preskorn, SH. Reducing the risk of drug-drug interactions: a goal of rational drug development. J clin Psychiat 1996; 57: 3–7.Google ScholarPubMed
84.Nemeroff, ChB, DeVane, CL, Pollock, BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiat 1996; 153: 311–20.Google ScholarPubMed
85.Chen, S, Chou, W-H, Blouin, RA, et al.The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996; 60: 522–35.CrossRefGoogle ScholarPubMed